Admedus Release: Cardiocel First Sales In MENA Region
• First sales of CardioCel® in Middle East and North Africa (MENA)
• Admedus anticipates further MENA approvals in 2016
Brisbane, Australia 3 February 2016
Admedus Limited (ASX: AHZ) today announced that it has achieved its first sales of CardioCel in the Middle East and North African (MENA) region. The initial sales of CardioCel have come through an early access program in Qatar. Admedus anticipates additional sales in other MENA countries in the near future.
“This is a positive step in the continued global launch of CardioCel and adds to growing revenue for Admedus. This first use of CardioCel in Qatar is particularly important, as the MENA region is one of the fastest growing healthcare areas worldwide and this bodes well for future sales,” said Admedus CEO, Mr Lee Rodne.
Admedus entered into a partnership in 2015 with Genpharm, a specialty marketing and sales healthcare company, to be its exclusive partner for CardioCel in the MENA region. Leveraging Admedus’ existing regulatory approvals outside the region, it is expected that the two companies will work together to produce a number of MENA country product marketing approvals in 2016.
CardioCel, Admedus’ lead bio-scaffold product, is used in the repair and reconstruction of cardiovascular defects, including reconstructing heart valves. It is preferred by surgeons due to its strength, elasticity and lack of hardening (calcification) at the site of surgery. Research shows the bio-scaffold has strong regenerative capabilities and incorporates over time in the repaired area to produce a ‘normal’ heart. To date, several thousand patients have been implanted with the bio-scaffold.
“Cardiovascular and congenital diseases are significant health issues in Qatar and in the MENA region, so this is an important initial use of CardioCel by surgeons there and will have long-reaching positive results for local patients,” said Mr Lee Rodne.
CardioCel is on market in Europe, the US, Canada, Malaysia, Hong Kong and Singapore and used in over 135 centres globally.
• Admedus anticipates further MENA approvals in 2016
Brisbane, Australia 3 February 2016
Admedus Limited (ASX: AHZ) today announced that it has achieved its first sales of CardioCel in the Middle East and North African (MENA) region. The initial sales of CardioCel have come through an early access program in Qatar. Admedus anticipates additional sales in other MENA countries in the near future.
“This is a positive step in the continued global launch of CardioCel and adds to growing revenue for Admedus. This first use of CardioCel in Qatar is particularly important, as the MENA region is one of the fastest growing healthcare areas worldwide and this bodes well for future sales,” said Admedus CEO, Mr Lee Rodne.
Admedus entered into a partnership in 2015 with Genpharm, a specialty marketing and sales healthcare company, to be its exclusive partner for CardioCel in the MENA region. Leveraging Admedus’ existing regulatory approvals outside the region, it is expected that the two companies will work together to produce a number of MENA country product marketing approvals in 2016.
CardioCel, Admedus’ lead bio-scaffold product, is used in the repair and reconstruction of cardiovascular defects, including reconstructing heart valves. It is preferred by surgeons due to its strength, elasticity and lack of hardening (calcification) at the site of surgery. Research shows the bio-scaffold has strong regenerative capabilities and incorporates over time in the repaired area to produce a ‘normal’ heart. To date, several thousand patients have been implanted with the bio-scaffold.
“Cardiovascular and congenital diseases are significant health issues in Qatar and in the MENA region, so this is an important initial use of CardioCel by surgeons there and will have long-reaching positive results for local patients,” said Mr Lee Rodne.
CardioCel is on market in Europe, the US, Canada, Malaysia, Hong Kong and Singapore and used in over 135 centres globally.